Phosphodiesterase 4D (PDE4D) has recently been implicated as a proliferationpromoting factor in prostate cancer and is over-expressed in human prostate carcinoma.
Introduction
Prostate cancer is the second leading cause of cancer deaths among men and the most commonly diagnosed non-cutaneous male cancer (1) . Although there are welldefined histologic alterations that have been identified in prostate cancer, the nature of this genetically heterogeneous disease has limited the identification of novel oncogenes that can be used as therapeutic targets. Using a transposon insertional mutagenesis screen, our laboratory previously identified phosphodiesterase 4D (PDE4D) as a novel proliferation-promoting factor for prostate cancer (2) . PDE4D was expressed in prostate cancer cell lines, but not primary prostate epithelial cells and knockdown of PDE4D significantly decreased prostate cancer cell growth and migration in vitro. Furthermore, knockdown of PDE4D by shRNA significantly reduced xenograft wet weights and xenograft cell proliferation in vivo. Subsequent studies that performed whole-genome sequencing of human prostate tumors detected internal rearrangements of the PDE4D
gene in approximately 20% of the tumors sequenced (3) . These results are consistent with results in other cancers that have rearrangements that are predicted to produce overexpression of short PDE4D isoforms (4) .
Phosphodiesterases (PDEs) hydrolyze cyclic AMP (cAMP) and GMP (cGMP)
and play a major role in cellular signaling. The PDE4 gene family has four isoforms: PDE4A, PDE4B, PDE4C, and PDE4D. In addition, the PDE4D gene has many variants attributed to alternative splicing and the use of multiple promoters (5, 6) . PDE4D enzyme degrades cAMP, but does not affect cGMP (5) . The distribution pattern of PDE4D variants varies within both cells and tissues (7) . In the prostate, PDE4D expression was observed in both the stroma and in epithelium and its hydrolytic activity was restricted to the cytosolic compartment (8) . In human prostate tumor microarrays representative of multiple stages of prostate cancer, PDE4D expression was most prominent in the epithelial cells (2) . PDE4D was over-expressed in prostate adenocarcinoma samples when compared to benign prostatic hyperplasia samples in a human prostatic tissue microarray (2) . inhibits prostate cancer progression. Transient increases in cAMP have been shown to be mitogenic in LNCaP prostate cancer cells by activation of extracellular signal-related kinase 1/2 (ERK1/2) while prolonged increases in cAMP led to growth arrest and neuroendocrine differentiation (9) . In contrast, increased cAMP levels in androgen insensitive PC3 cells resulted in growth inhibition (10) . cAMP/protein kinase A (PKA) activity has also been shown to affect the activity of the androgen receptor (AR) leading to increased AR-responsive gene expression in androgen-independent conditions (11, 12) .
In addition, cAMP/PKA activity negatively regulates the hedgehog pathway (HH) in some cell types including leukemia cells and basal cell carcinomas and increasing cAMP signaling leads to growth arrest and death (13, 14) . While the effects of PKA on the hedgehog pathway have not been investigated in prostate cancer cells, the hedgehog pathway has been shown to be an important driver of the prostate cancer phenotype in DU145 and PC3 (15) . Furthermore, both DU145 and PC3 cells are growthinhibited by PDE4D knockdown (2) . In prostate cancer, increased expression of hedgehog pathway components is correlated with high Gleason grade (grade 7-8) and lymph node metastasis (16) . In prostate development, epithelial cells secrete sonic hedgehog which binds to the mesenchymal smoothened (Smo) receptors which is essential for the formation of prostate buds (17) . While it is clear that the hedgehog pathway is a critical pathway in prostate cancer progression, it remains unclear whether paracrine, autocrine or both mechanisms of hedgehog signaling are important for driving prostate cancer progression (18) . However, based upon the effects of cAMP signaling the literature suggests that alterations in PDE4D expression seen in the prostate cancer could potentially affect many signaling pathways including MAPK, AR, and hedgehog.
This suggests that pharmacological inhibition of PDE4D could affect several pathways that are linked to prostate cancer. Phosphodiesterases have historically been attractive experimental targets for a wide variety of conditions including: erectile dysfunction (PDE5), depression (PDE4D), asthma, chronic obstructive pulmonary disorder (COPD) (PDE4D), and inflammation (PDE4D, PDE7) (19) . Currently, the FDA-approved PDE inhibitors include a variety of PDE5 inhibitors utilized in the treatment of erectile dysfunction and a non-subtype selective PDE4 inhibitor, roflumilast, utilized in combination therapy for COPD (in combination with brochodilator) (20) . First generation PDE4D inhibitors, such as rolipram, were initially developed and tested in the treatment of respiratory disorders, and second generation PDE4D inhibitors such as NVP-ABE171 (21) and cilomilast (Ariflo, SB207499) were designed to have an improved potency and subtype selectivity compared to first generation inhibitors (22) . NVP-ABE171 was reported to have increased potency and selectivity for PDE4D compared to cilomilast, although both small molecule inhibitors were more selective for PDE4D than other PDE4 family members (21) . NVP-ABE171 has been tested with in vitro and in vivo models of airway inflammation and was generally effective and well tolerated in rats and mice (21) . Among PDE4D selective inhibitors, cilomilast was the most extensively tested in human clinical trials (23), but cilomilast was not FDA-approved due to a lack of efficacy in Phase III clinical studies for respiratory diseases. However, these clinical trials established doses (15 mg twice daily) of cilomilast that were safe for human use, with mild, transient side effects (22) .
Currently, the effects of PDE4D in cancer are not well understood and only few studies examined the role of PDE4D and its inhibitors in cancer therapy. PDE4D inhibitors have not been tested in prostate cancer models. Studies in A549 lung cancer cells demonstrated that transforming growth factor-β (TGF-β) stimulation increased PDE4D expression and activity which promoted epithelial to mesenchymal transition, which could be attenuated with PDE4D inhibitor rolipram (24) . A second study revealed that hypoxia via hypoxia inducible factor-α (HIF1-α) regulated PDE4D in a lung cancer model and that in vivo treatment with first generation PDE4D inhibitor, rolipram, decreased A549 xenograft weight and proliferation (25) . Recently, a third study indicated that PDE4D expression increased in melanoma and endometrial carcinomas and that a 26B, a novel PDE4D inhibitor, decreased in vitro growth of HGC-27 gastric carcinomas cells and A375 melanoma cells (26) .
Based on our previous studies that showed that stable knockdown of PDE4D in cell lines reduced the growth of the prostate cancer epithelial cells and the published literature demonstrating in vivo efficacy on lung, melanoma, and gastric cancer xenografts, we hypothesized that the second-generation PDE4D inhibitors NVP-ABE171 and cilomilast would reduce the growth of prostate cancer cells. We chose to use two second-generation PDE4D inhibitors based on their selectivity for PDE4D as well as their previous use in other disease models with limited side effects observed in both humans and animal models. The results of the current study demonstrate that PDE4D inhibitors are effective at reducing growth of prostate cancer cells both in vivo and in vitro. In addition, PDE4D inhibition also reduced growth of benign prostate cells and modestly decreased the overall prostate weight in wild type C57BL-6 mice.
Materials and Methods
Cell lines: Prostate cell lines BPH1, (LNCaP (ATCC), and LNCaP-C4 (27) epidermal growth factor, 1 μg/mL ITS (Lonza), and 100 µg/mL pen-strep (29) . P2 cells were cultured as previously described (30 Western Blots: Blots were performed as previously described (31). Primary antibodies for pERK1/2 and total ERK1/2 were obtained from Cell Signaling.
Microculture assays: 5,000 to 7,500 cells were plated in microculture devices as previously described (32) . LNCaP or LNCaP-C4 cells were cultured with either UGSM-2, UGSM-2 + exogenous sonic hedgehog (Shh, Curis), or Gli3-/-UGSM cells (UGli3
Drugs were added on day 1 and replenished until day 5. Following the growth period, cell proliferation was quantified using an EdU assay kit (Invitrogen) or RNA was extracted using DynaBeads (Invitrogen) (33) . EdU assay images were obtained on an intensities were determined using ImageJ v1.38 (NIH). % EdU (+) cells were obtained by dividing total EdU (+) cells to total cell number (Hoescht-nuclear stain) X 100. Cell proliferation was assessed for significant differences by Wilcoxon Mann-Whitney test.
Significant differences have a p-value <0.05. Immunohistochemistry: Immunohistochemistry was performed as previously described using antibodies for E-cadherin (Cell Signaling), smooth muscle actin (Sigma), p63 (Santa Cruz Biotechnology), Ki67 (Vector Laboratory, VP-K452) or p21 (Santa Cruz Biotechnology, sc-397) (31). Slides were dewaxed, rehydrated with a graded alcohol series, antigen retrieval was performed with antigen unmasking solution (Vector Labs), and endogenous peroxidases were quenched by incubation in H 2 O 2 . Slides were blocked with 2.5% serum, incubated with primary antibody overnight, washed, and incubated with biotinylated secondary antibody (Vector Labs) followed by incubation with ABC reagent (Vector Labs), and color development with DAB (Vector Labs). Slides were counterstained with haematoxylin, dehydrated, and mounted. TUNEL assays were performed as specified by the manufacturer using the DeadEnd Colormetric TUNEL assay system (Promega) and were counterstained with haematoxylin. Slides were imaged with a 20x objective on a Leica DMLB microscope and acquired using QCapture Figure   3C ). However, in combination sub-optimal doses of NVP-ABE171 and cyclopamine were able to decrease growth compared to control or either treatment alone.
qRT-PCR:
Since there are conflicting reports regarding the importance of autocrine and paracrine hedgehog signaling in prostate cancer, the connection between PDE4D and the sonic hedgehog pathway was explored further using a relevant model of stromal- ABE171 treated mice has a statistically significant reduction in prostate weight and cilomilast treatment resulted in a similar trend, but the overall body weight and wet weights of the lungs, liver, spleen and seminal vesicles of the mice were not impacted ( Figure 5A-B and data not shown) . IHC was performed on prostate sections to determine the effects of PDE4D inhibition on morphology and organization ( Figure 5C ). The overall morphology and organization of the prostate appeared normal in the cilomilast and NVP-ABE171 treated prostates as assessed by hematoxylin and eosin (H&E) staining. In addition, markers for stromal (smooth muscle actin) and epithelial (E-cadherin) compartments were unchanged. While there was a trend to an increase in the basal epithelial subtype (p63), this increase was not statistically significant. Neuroendocrine markers, neuropilin and chromogranin A were examined due to a previous report that in an in vitro model PDE inhibitors caused a neuroendocrine differentiation (9) . However, positive staining for neuroendocrine markers (as compared with a positive control) was not observed in any of the control, cilomilast or NVP-ABE171 treated prostates (data not shown). The expression of hedgehog activated genes, Shh, Gli1, and Ptch1 in the mouse prostate was not significantly affected by cilomilast or NVP-ABE171 treatment (data not shown). However, this was not unexpected since the level of hedgehog signaling in the adult mouse prostate is quite low compared to the human prostate or the developing prostate (39) .
The effects of PDE4D inhibition were also measured in vivo using a prostate were only decreased by approximately 50%, the effect of PDE4D inhibitors in vivo was robust where cilomilast and NVP-ABE171 decreased xenograft wet weight 85% and 70%, respectively. In order to identify a potential mechanism to explain how PDE4D inhibitors decreased the size of LNCaP-C4 xenografts, xenografts were fixed and paraffin embedded to examine proliferation (Ki-67), apoptosis (TUNEL), and senescence 
Discussion
Resistance to existing prostate cancer therapies is a constant problem in prostate cancer as current treatments are not curative. Therefore, targeting novel pathways may provide alternatives to existing treatments for prostate cancer. Previous studies in our laboratory have identified PDE4D as a proliferation-promoting factor that has increased expression in prostate cancer (2) . Since phosphodiesterases are good targets for small molecule inhibitors, the effects of PDE4D inhibitors were investigated as potential therapies for prostate cancer. To date, there have been no studies published which investigate PDE4D inhibitors in prostate cancer, although others have investigated the potential for use of PDE4D inhibitors in cancer therapy in vivo using animal models of cancer of lung cancer (25) and in vitro studies have shown efficacy of PDE4D inhibitors in lung, melanoma, and leukemia (25, 26, 40) . The results of these studies suggest that PDE4D inhibition has the potential to be an effective prostate cancer therapy. These studies demonstrate the efficacy of PDE4D inhibitors in both in vivo and in vitro prostate cancer models. In vitro moderate inhibition of LNCaP-C4 and P2 cell growth was observed and in vivo dramatic decreases in LNCaP-C4 xenografts wet weight were observed PDE4D inhibitor treated mice. It is unclear why the in vivo response to PDE4D inhibitors was so strong compared to the in vitro response, however; these results highlight the importance of examining the effect of potential therapeutics using multiple experimental approaches (41) . While in vitro models of cell culture are models of growth in an isolated cell population, they provide a framework where the mechanism of action of a particular drug or pathway can be interrogated. In (29), were unaffected by either cilomilast or NVP-ABE171 treatment. This is further supported by the in vivo data, where PDE4D inhibition had dramatic effects prostate cancer xenografts, but only modest effect on the wild-type prostate. In addition, in vivo the effect of the inhibitors was not apparent in many other tissues (lungs, liver, spleen or seminal vesicles) and the overall weight of the animals was not impacted. These data suggest an overall selectivity for transformed cell populations both in vivo and in vitro.
In vitro mechanistic studies revealed that PDE4D inhibition affected several PKAmediated pathways, but only high doses of NVP-ABE171 lead to a decrease in MAPK and AR signaling pathways. However, the inhibition of hedgehog signaling pathway was best correlated with growth inhibition, which was observed at doses as low as 50 nM NVP-ABE171. A previous study used purified PDE4A, B, C, and D to determine the IC 50 of both NVP-ABE171 and cilomilast. NVP-ABE171 had the lowest IC 50 for PDE4D (1.5 nM), the next lowest was PDE4B (34 nM) and the IC 50 values for PDE4A and PDE4C
were both greater than 600 nM (21) . For cilomilast the results showed a similar trend for IC 50 , but with less potency where the IC 50 for PDE4D and PDE4B was the lowest at 63 nM and 288 nM, respectively. As a comparison, the prototypical PDE4 inhibitor rolipram is most potent for inhibition of PDE4A (IC 50 of 3 nM) followed by PDE4B (130 nM) and 
PDE4D (240 nM)(44). The
In vitro studies demonstrated growth inhibition by NVP-ABE171 effects doses as low as 40-50 nM and cilomilast doses of 5 μM, which have the potential to inhibit both PDE4D and PDE4B. Further experiments will be required to determine the relative contribution of each PDE4 isoform to the effects of NVP-ABE171 and cilomilast. Oftentimes inhibition in whole cells or in vivo requires a higher concentration of the drug, which is consistent with treatments used in this study. This suggests that the results observed are likely due to the inhibition of PDE4D, but the impact of PDE4B cannot be completely excluded. The role of the hedgehog pathway is well-characterized in the context of prostate development, where paracrine signaling occurs from epithelial cells that secrete shh that binds to Smo on the mesenchymal cells and ultimately promotes prostatic budding and development (17) . In the adult mouse prostate hedgehog activity is diminished compared with the developing prostate, but in the human adult prostate hedgehog signaling remains relatively high (39) . Both human prostate tumors and mouse models of prostate cancer have increased hedgehog expression and activity, particularly in aggressive and androgen-independent cancers (15, 45) . However, in prostate cancer it is unclear whether the paracrine hedgehog signaling remains intact or if there is autocrine signaling that occurs. Studies examining prostate tumor histology have demonstrated that the localization of hedgehog pathway components can be altered in tumors (16, 46) . Epithelial expression of SMO, PTCH, and SHH increased and the expression of stromal hedgehog components GLI1, SMO, and PTCH were decreased (46) . In contrast a study by Shigemura et al. demonstrated that GLI1 expression was increased in prostate cancer fibroblasts compared to normal fibroblasts (47) . Additional studies by Shaw and colleagues demonstrated that either paracrine and autocrine hedgehog signaling in stroma can promote prostate cancer growth in vivo (18) . Overall, the data suggests there may be heterogeneity in both the cell type (epithelial vs. stromal) and mechanism of hedgehog signaling (paracrine vs. For in vivo studies, doses of drugs and oral delivery method were chosen based on previous animal models in which NVP-ABE171 or cilomilast were used (21) . Results of these studies suggest that PDE4D inhibitors, cilomilast and NVP-ABE171, are efficacious and safe in vivo using a relevant xenograft mouse model of prostate cancer.
In vivo studies with the small molecule PDE4D inhibitors using the LNCaP-C4 xenograft model demonstrated that administration of NVP-ABE171 or cilomilast for 6 weeks decreased the wet weight of the xenografts. The data demonstrated that both NVP-ABE171 and cilomilast significantly increased apoptosis, while NVP-ABE171 also decreased proliferation. These results suggested that PDE4D inhibition in vivo is efficacious as an anti-prostate cancer therapy in LNCaP-C4 xenografts by causing an increase in apoptosis. In addition to decreasing prostate xenograft size, in wild-type mice PDE4D inhibitor treatment decreased prostate weight without an impact on total body weight. Additionally, the data indirectly suggest that PDE4D inhibition is not affecting the level of androgens or AR signaling, since the histology of the H&E from the prostate appears normal and does not demonstrate the atrophy and loss of ducts observed in castrated mice (50) . Also, the wet weight of seminal vesicles, which are highly androgen After six weeks animals were sacrificed and prostate were collected. Average weights of the A) prostate and B) total animal are represented in the graphs and error bars represent the SEM. Statistical analysis was performed using an ANOVA followed by Tukey's test for individual comparisons (* NVP-ABE171 P<0.05 versus vehicle control).
C) IHC was performed on prostates that were fixed and paraffin sectioned. Sections were stained by H&E to assess overall morphology and IHC was performed to examine epithelial (E-cadherin), stromal (SMA-smooth muscle actin), and basal cell (p63) markers. 
